Chen et al.57evaluated AF on chronic myelogenous leukemia (CML) cell and animal models, as an alternative therapy to overcome acquired resistance to Imatinib mesylate (IM), a drug resistance mainly due to mutation in Bcr‐Abl.58, 59. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.